Sickle Cell Therapy in 2026: Comparing Every Treatment Option

Introduction: Why 2026 Is a Turning Point for Sickle Cell Therapy

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. It affects an estimated 100,000 Americans, disproportionately impacting Black and African American individuals. For decades, care focused mainly on managing symptoms. That has changed.

Since the first gene therapies were approved in December 2023, the field has moved quickly. Several developments now shape the landscape:

• Casgevy has expanded eligibility to young children.
• Oxbryta has been withdrawn from global markets.
• bluebird bio has rebranded as Genetix Biotherapeutics.
• A maturing pipeline of investigational therapies (mitapivat, risto-cel, reni-cel, and in vivo gene editing) is approaching key milestones.

This article offers a comprehensive, unbiased comparison across every major therapy category: conventional, curative, and investigational. It is written for patients, caregivers, clinicians, and payers. It closes with a practical decision-making framework rather than a simple list of options.

Understanding the Treatment Landscape: What “Options” Actually Means in 2026

SCD treatment is not one choice. It is a spectrum that runs from symptom management to curative intervention. Throughout this guide, therapies are grouped into three broad categories:

1. Conventional disease-modifying therapy: hydroxyurea, transfusions, and other approved drugs
2. Curative cellular and gene therapy (ex vivo): stem cell transplant, Casgevy, and Lyfgenia
3. The emerging pipeline: next-generation editing, oral agents, and in vivo approaches

The curative options are the newest, but they are not the right fit for everyone. Manufacturers have estimated that only about one-sixth to one-fifth of the SCD population may be eligible for current gene therapies. For most patients, conventional options remain essential.

The newest therapy is not automatically the best one. Eligibility, goals of care, and personal risk tolerance should drive each decision.

Conventional Management: The Foundation of SCD Care

Conventional therapy remains first-line treatment and the most widely used path for the majority of patients, including many who may eventually pursue a cure.

Hydroxyurea: The Long-Standing First-Line Therapy

Hydroxyurea was approved in 1998 and is still the most widely prescribed disease-modifying therapy for SCD.

How it works: It induces production of fetal hemoglobin (HbF). This form of hemoglobin does not sickle, so higher levels reduce the deformation of red blood cells.

What the evidence shows: Hydroxyurea improves anemia, reduces the frequency of pain crises, and lowers the risk of hospitalization and acute chest syndrome.

Practical considerations:

• Patients must take it every day, and adherence can be difficult over many years.
• Regular blood count monitoring is required to manage side effects such as low white cell counts.

Even so, its long safety record and oral dosing make it the starting point for most treatment plans.

Chronic Blood Transfusions

Regular transfusions replace sickled red cells with healthy donor cells. They play a central role in stroke prevention, especially in children with abnormal transcranial Doppler screening. They are also used to manage acute complications.

Transfusions have significant limitations:

• Iron overload: Repeated transfusions cause iron to build up in the body, which requires chelation therapy.
• Alloimmunization: Patients can develop antibodies against donor blood, which makes future matching harder.
• Logistical burden: Frequent clinic visits disrupt school, work, and family life.

Other Approved Drug Therapies and the Oxbryta Withdrawal

Two other FDA-approved options focus on reducing pain crises:

• L-glutamine (Endari, 2017): An oral powder believed to reduce oxidative stress in red blood cells.
• Crizanlizumab (Adakveo, 2019): An intravenous antibody that targets P-selectin, which helps prevent cells from sticking to blood vessel walls.

Voxelotor (Oxbryta), also approved in 2019, was once a popular oral therapy that worked by modifying hemoglobin. In September 2024, Pfizer voluntarily withdrew Oxbryta from all global markets. Post-marketing data had shown an imbalance in vaso-occlusive crises and fatal events compared with placebo.

What this meant for patients: People taking Oxbryta had to transition to other therapies, usually under close hematologist supervision. The withdrawal also left a gap in oral hemoglobin-modifying treatment. That gap is one reason new oral candidates such as mitapivat are drawing so much attention in 2026.

Allogeneic Stem Cell Transplant: The Original Cure

Before gene therapy, allogeneic hematopoietic stem cell transplantation (HSCT) was the only long-established curative option. A healthy donor’s stem cells replace the patient’s blood-forming system, and the new system produces normal red blood cells.

HSCT has two main limiting factors:

• Donor availability: Fully matched sibling donors are rare. Only a minority of patients have one.
• Graft-versus-host disease (GVHD): The donor’s immune cells may attack the recipient’s tissues. This risk rises with less closely matched donors.

To widen access, researchers are studying haploidentical transplant protocols, which use half-matched donors such as parents or siblings. These protocols make it possible for many more patients to find a donor.

How HSCT compares with gene therapy: Matched sibling transplant has strong curative outcomes and decades of follow-up data. Gene therapy uses the patient’s own cells, which removes both the need for a donor and the risk of GVHD. However, gene therapy still requires intensive conditioning chemotherapy.

The Gene Therapy Era: Casgevy and Lyfgenia Compared

In December 2023, the FDA approved Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), now from Vertex and CRISPR Therapeutics, and Genetix Biotherapeutics, respectively. Both were approved for patients aged 12 and older with recurrent vaso-occlusive crises (VOCs). They were the first gene therapies approved for SCD with curative intent.

How They Work: Gene Editing vs. Gene Addition

• Casgevy uses CRISPR/Cas9 to edit the BCL11A gene, which normally switches off fetal hemoglobin production after infancy. Disrupting it restores high HbF levels.
• Lyfgenia uses a lentiviral vector to add a functional, modified beta-globin gene. That gene produces an anti-sickling hemoglobin called HbA T87Q.

The key distinction: Casgevy edits an existing gene, while Lyfgenia adds a new working gene. Both aim to reduce sickling. As the Sickle Cell Disease Association of America has noted, both strategies involve roughly the same patient journey and potential issues.

Efficacy Data Side-by-Side

Feature	Casgevy	Lyfgenia
Approach	CRISPR/Cas9 gene editing	Lentiviral gene addition
Target	BCL11A (raises HbF)	Adds modified beta-globin (HbA T87Q)
Key result	Elimination of painful VOCs in more than 90% of patients	28 of 32 (88%) achieved complete resolution of vaso-occlusive events (VOEs)
Hospitalizations	Complete elimination of VOC-related hospitalizations in all evaluable patients	Not the primary reported measure
Evaluation window	Ongoing single-arm trial (CLIMB-121), 44 patients evaluated for safety	6 to 18 months post-infusion

An important caveat: Both trials used small patient groups and had no randomized control arms. The results are strong, but long-term follow-up is still building.

2026 Update: Casgevy’s Pediatric Expansion

In July 2026, the FDA expanded Casgevy’s approval to children as young as 2 years old. This makes it the first gene therapy approved for young children with SCD.

The change matters because SCD causes damage over time. Each crisis can harm the brain, kidneys, lungs, and other organs, and that damage adds up. Treating patients earlier may prevent much of it.

Genetix is pursuing a similar pediatric expansion for Lyfgenia through the HGB-210 study, which enrolls patients under 12.

The Conditioning Regimen: The Hidden Barrier

Both therapies require myeloablative conditioning with busulfan chemotherapy before the modified cells are infused. This step clears the bone marrow to make room for the edited cells. Experts describe the regimen as harsh. It carries a high risk of infertility, along with hair loss, mouth sores, infection risk, and an extended hospital stay.

For many eligible patients, conditioning is the deciding factor against gene therapy. It is a major reason real-world uptake has been slow.

Why Real-World Uptake Has Lagged Behind Approval

More than two years after approval, uptake remains slow. As of mid-2026, Genetix reported that Lyfgenia had treated just over 100 patients, even though broad reimbursement was already in place. The vast majority of eligible patients remain untreated.

Several factors contribute:

• Conditioning toxicity and infertility risk: Many patients, especially young adults, are unwilling to accept these trade-offs.
• Lengthy timelines: The process involves multiple cell collection cycles, months of manufacturing, and a prolonged hospital stay for conditioning and engraftment.
• Treatment center access: Only a limited number of qualified centers can deliver these therapies.
• Specialist access gaps: Only about 30% of adults with SCD report regular access to a specialist. Patients without a hematologist rarely get referred for gene therapy evaluation.

BioPharma Dive has reported that patient interest consistently outpaces actual treatment numbers. Many people want to learn about a cure but are not able or ready to begin the process.

Market Shifts: The Genetix Rebrand and What It Signals

In 2025, bluebird bio was acquired in a private-equity buyout and rebranded as Genetix Biotherapeutics. The company projected that Lyfgenia and its pain drug Journavx would generate combined revenue growth of roughly 185% in 2026 compared with 2025.

The rebrand and growth targets point to a few trends:

• Gene therapy companies are shifting from survival mode toward sustained commercial execution.
• Pairing a curative therapy with a broader pain product suggests a portfolio strategy rather than reliance on a single asset.
• The ongoing HGB-210 pediatric work shows a long-term commitment to the SCD space.

Together, these moves suggest the gene therapy market is maturing, even though patient uptake remains modest.

The Emerging Pipeline: What Is Coming Next

Most published overviews stop at the approved therapies. The candidates below represent the investigational landscape as of late 2026, and several are close to key milestones.

Reni-cel: A New CRISPR Mechanism Shows a “Functional Cure”

In April 2026, the Cleveland Clinic-led multicenter RUBY Trial, published in the New England Journal of Medicine, reported results for reni-cel (renizgamglogene autogedtemcel, from Editas Medicine). In the trial, 27 of 28 patients (96%) with severe SCD had no painful crises after treatment. Physicians described this outcome as a “functional cure.”

How it works: Reni-cel uses CRISPR-Cas12a to edit the HBG1 and HBG2 gene promoters, which directly increases fetal hemoglobin production.

Durability: Patients remained free of painful crises for up to two years after treatment.

How it differs from Casgevy: Casgevy uses Cas9 to disrupt the BCL11A repressor. Reni-cel uses a different enzyme and edits the fetal globin genes’ own regulatory regions. However, reni-cel still uses ex vivo manufacturing and conditioning.

Risto-cel: Base Editing Enters Late-Stage Development

Beam Therapeutics’ risto-cel (formerly BEAM-101) was studied in the BEACON trial, which reported data on 31 patients. Results included:

• Mean HbF induction above 60%
• HbS (sickle hemoglobin) reduced below 40%
• Resolution of hemolysis markers
• No severe VOCs reported after engraftment, based on data spanning late 2025 through 2026

How base editing differs: Base editing changes a single DNA “letter” without cutting both strands of DNA. This precision may reduce unintended edits compared with conventional CRISPR cutting.

Near-term milestone: Beam is targeting an FDA submission as early as the end of 2026, making risto-cel a key candidate to watch.

Mitapivat: The First Potential Oral Therapy in This New Wave

Agios Pharmaceuticals’ mitapivat is a pyruvate kinase (PK) activator already approved for other hemolytic anemias. In July 2026, it received FDA Priority Review for SCD, with a Prescription Drug User Fee Act (PDUFA) date of November 1, 2026. If approved, it would be the first oral PK activator for SCD.

How it works: Mitapivat improves energy metabolism inside red blood cells. Better-energized cells are more resilient and less prone to sickling and breaking down. This approach is distinct from hemoglobin-modifying drugs and gene-based therapies.

Why a non-curative pill still matters:

• It is convenient to take.
• It avoids chemotherapy and its risks.
• It could serve patients who are ineligible for gene therapy or prefer not to pursue it.

The Next Frontier: In Vivo Gene Editing

Current gene therapies are ex vivo: cells are collected, edited in a lab, and then returned to the patient after conditioning. In vivo editing would instead deliver the editing tools directly into the body, typically using lipid nanoparticles (LNPs).

If successful, in vivo editing could eliminate:

• Stem cell collection
• Chemotherapy conditioning
• Ex vivo manufacturing

This could dramatically improve access and reduce toxicity. Collaborations such as the Orna and Vertex in vivo LNP work are early-stage but point in an important direction. Approval is likely years away, but in vivo editing is a meaningful long-term goal for the field.

Cost, Coverage, and Access in 2026

SCD is expensive to manage over a lifetime. The median lifespan for people with SCD is about 45 years, and decades of hospitalizations, emergency visits, transfusions, and lost productivity add up to a substantial cumulative burden. This lifetime cost is the context in which payers evaluate one-time curative therapies, even though those therapies carry very high upfront costs.

Key coverage pathways:

• CMS Cell and Gene Therapy Access Model: The Centers for Medicare & Medicaid Services (CMS) covers roughly half of SCD patients through Medicaid. This voluntary model helps state Medicaid programs negotiate and afford access to gene therapy.
• Comparative economic research: A 2026 cost-effectiveness analysis in Blood compared haploidentical transplant, gene therapy, and standard care. It reflects growing interest in comparing curative approaches on both outcomes and economics.

Equity remains a central concern. Limited specialist access and state-by-state differences in Medicaid coverage strongly influence who can realistically pursue a cure. Two patients with identical disease may face very different options depending on where they live.

A Practical Framework for Choosing a Treatment Path

Patients and families can work through the following questions with their care team:

1. Age and eligibility: Does the patient meet age and crisis-history criteria? (Casgevy now covers ages 2 and up; Lyfgenia covers ages 12 and up.)
2. Disease severity: How frequent and severe are the crises? Is there evidence of organ damage?
3. Donor availability: Is a matched sibling or a haploidentical donor available for HSCT?
4. Fertility priorities: Is future biological parenthood important, and is fertility preservation feasible?
5. Risk tolerance: Is the patient willing to undergo busulfan conditioning and a long hospital stay?
6. Access: Is there an experienced treatment center within reach, and does the patient’s coverage support referral?

Comparative summary of pathways:

Pathway	Options	Best suited for
Manage symptoms	Hydroxyurea, transfusions, L-glutamine, crizanlizumab	Most patients; first-line care; those avoiding intensive procedures
Established cure	HSCT, Casgevy, Lyfgenia	Eligible patients with severe disease who accept conditioning risks
Investigational / near-term	Reni-cel, risto-cel, mitapivat	Trial-eligible patients or those seeking new mechanisms

No single therapy is universally the best choice. The right path depends on individual clinical and personal factors. Shared decision-making with a hematologist experienced in SCD curative therapies is essential.

Questions to Ask the Care Team

Patients and caregivers may find it helpful to bring these questions to appointments:

• Is the patient eligible for gene therapy based on crisis history and age?
• What does the conditioning process actually involve, and how long is the hospital stay?
• What fertility preservation options are available before treatment?
• Is there a clinical trial the patient could qualify for (reni-cel, risto-cel, or mitapivat)?
• What does the patient’s insurance or Medicaid plan cover?
• How many gene therapy patients has this center treated? Center experience matters given the complexity of the ex vivo process.
• What is a realistic timeline from cell collection to engraftment? The process often takes many months.

The Road Ahead: What to Watch Through the Rest of 2026 and Beyond

Near-term catalysts:

• November 1, 2026: The FDA’s decision on mitapivat for SCD
• End of 2026: A potential FDA submission for risto-cel
• Ongoing: Pediatric expansion data for Lyfgenia from the HGB-210 study

Longer term, in vivo editing could transform access by removing the steps that currently stop many patients: cell collection, conditioning chemotherapy, and specialized manufacturing.

The field is changing quickly, so this guide should be treated as a living reference point rather than a final answer.

Conclusion: Matching the Right Therapy to the Right Patient

This guide has covered the full spectrum of SCD care: conventional management, stem cell transplant, approved gene therapies, and an increasingly promising pipeline.

The core message is that 2026 offers more legitimate options than ever. Even so, eligibility, access, and personal risk tolerance should guide decisions, not hype. Real barriers remain, including conditioning toxicity, cost burden, and limited specialist access. These must be weighed honestly alongside the efficacy data. Because this field is moving so fast, staying current is part of making a sound decision.

Next Steps: Talk to a Specialist About Your Options

Patients and families should consult a hematologist or a comprehensive SCD treatment center to review eligibility across conventional, curative, and trial-based options. When standard therapies have not provided adequate control, enrolling in a clinical trial for an emerging therapy such as reni-cel, risto-cel, or mitapivat may be worth discussing.

New approvals and trial data are expected throughout 2026 and beyond. Readers are encouraged to bookmark this resource and return as the landscape continues to change.